Inari Medical (NARI) Stock Price, News & Analysis

Company Overview

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

Key Stats

• Today's Range: $79.97 to $79.97
• 50-Day Range: $79.97 to $79.97
• 52-Week Range: $39.76 to $79.99
• Volume: N/A
• Average Volume: 1.33 million shs
• Market Capitalization: $4.68 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.22
• Consensus Rating: Hold

NARI Stock Analysis - Frequently Asked Questions

How have NARI shares performed this year?

Inari Medical's stock was trading at $51.05 on January 1st, 2025. Since then, NARI shares have increased by 56.7% and is now trading at $79.97.
View the best growth stocks for 2025 here.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) announced its earnings results on Wednesday, February, 28th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of $0.01 by $0.09. The firm's revenue was up 22.5% compared to the same quarter last year.
Read the conference call transcript.

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an initial public offering (IPO) on Friday, May 22nd 2020. The company issued 7,300,000 shares at $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Inari Medical's top institutional shareholders include SoundView Advisors Inc. (0.01%), TIG Advisors LLC and First Sabrepoint Capital Management LP. Insiders that own company stock include Donald B Milder, Andrew Hykes, Thomas Tu, William Hoffman, Mitch C Hill and Rebecca Chambers.
View institutional ownership trends.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inari Medical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Netflix (NFLX) and Visa (V).

Company Calendar

• Last Earnings: 2/28/2024
• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NARI
• CIK: 1531048
• Web: www.inarimedical.com
• Phone: 877-923-4747
• Fax: N/A
• Employees: 800
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $69.22
• High Stock Price Target: $80.00
• Low Stock Price Target: $47.00
• Potential Upside/Downside: -13.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.14
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.64 million
• Net Margins: -13.68%
• Pretax Margin: -9.29%
• Return on Equity: -10.09%
• Return on Assets: -6.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.77
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $493.63 million
• Price / Sales: 9.48
• Cash Flow: $0.09 per share
• Price / Cash Flow: 906.95
• Book Value: $8.07 per share
• Price / Book: 9.91

Miscellaneous

• Outstanding Shares: 58,540,000
• Free Float: 52,338,000
• Market Cap: $4.68 billion
• Optionable: Optionable
• Beta: 1.02